Thinking.., page-23

their costs will ramp up with the phase 1 accelerating as well as all the senior management they are bringing on board. They are thinking of possibly opening up another site for the phase 1 trial once they get to the highest dosage… again more money.

the pipeline they want to expand will again cost more money and teams will expand.

I would actually be concerned if they didn’t burn through more cash in the coming quarters, because it would mean they are not running at 100%.

I would be surprised if we don’t raise more capital in mid to late 2022, but by that stage the phase 1 trial will be nearing completion and data from patients with the highest dose may already be available.

And I highly suspect we will be trading much higher than 36.5 cents.